{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"Morpheus-panBC","nct_id":"NCT03424005","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=morpheus-panbc-nct03424005. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Morpheus-panBC","arms":[{"description":"1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.\n\nEnrollment is closed.","label":"Atezolizumab + Nab-Paclitaxel","type":"ACTIVE_COMPARATOR"},{"description":"1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.\n\nEnrollment is closed and participant follow-up is complete.","label":"Atezolizumab + Nab-Paclitaxel + Tocilizumab","type":"EXPERIMENTAL"},{"description":"1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.\n\nEnrollment is closed.","label":"Atezolizumab + Sacituzumab Govitecan","type":"EXPERIMENTAL"},{"description":"2L CIT-naïve participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).\n\nParticipants who progressed on treatment may have the option of receiving atezolizumab along with chemotherapy (chemo) during stage 2, provided they meet the eligibility criteria.\n\nEnrollment is closed and participant follow-up is complete.","label":"Capecitabine","type":"ACTIVE_COMPARATOR"},{"description":"2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.\n\nParticipants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.\n\nEnrollment is closed and participant follow-up is complete.","label":"Atezolizumab + Ipatasertib","type":"EXPERIMENTAL"},{"description":"2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.\n\nPatients who experience loss of clinical benefit as determined by the investigator or unacceptable toxicity related to SGN-LIV1A will be given the option of receiving Atezolizumab + chemo during Stage 2, provided they meet the eligibility criteria.\n\nEnrollment is closed and participant follow-up is complete.","label":"Atezolizumab + SGN-LIV1A","type":"EXPERIMENTAL"},{"description":"2L-CIT-naïve participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.\n\nParticipants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.\n\nEnrollment is closed and participant follow-up is complete.","label":"Atezolizumab + Selicrelumab + Bevacizumab","type":"EXPERIMENTAL"},{"description":"2L CIT-naïve participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naïve participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemo (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.\n\nEnrollment is closed and participant follow-up is complete.","label":"Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus abemaciclib plus fulvestrant until unacceptable toxicity or disease progression determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Abemaciclib + Fulvestrant","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Ribociclib (Dose #1) + Fulvestrant","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Ribociclib (Dose #1) + Letrozole","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Ribociclib (Dose #2) + Fulvestrant","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Ribociclib (Dose #2) + Letrozole","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus abemaciclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Abemaciclib + Letrozole","type":"EXPERIMENTAL"},{"description":"HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.\n\nEnrollment is closed.","label":"Inavolisib (Dose #1) + Trastuzumab Deruxtecan","type":"EXPERIMENTAL"},{"description":"HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.\n\nEnrollment is closed.","label":"Inavolisib (Dose #2) + Trastuzumab Deruxtecan","type":"EXPERIMENTAL"},{"description":"Participants with locally advanced or metastatic, HR+, HER2- participants will receive empagliflozin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Empagliflozin + Inavolisib (Dose #2) + Fulvestrant ± Palbociclib","type":"EXPERIMENTAL"},{"description":"Participants with locally advanced or metastatic, HR+, HER2- participants will receive metformin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Metformin + Inavolisib (Dose #2) + Fulvestrant ± Palbociclib","type":"EXPERIMENTAL"},{"description":"Participants will receive inavolisib plus atirmociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Atirmociclib (Atirmo) + Fulvestrant","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus abemaciclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #1) + Abemaciclib + Letrozole","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus abemaciclib plus giredestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #1) + Abemaciclib + Giredestrant","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus abemaciclib plus giredestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Abemaciclib + Giredestrant","type":"EXPERIMENTAL"},{"description":"HR+ participants will receive treatment with inavolisib plus ribociclib plus giredestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.","label":"Inavolisib (Dose #2) + Ribociclib (Dose #1) + Giredestrant","type":"EXPERIMENTAL"}],"collaborators":["Gilead Sciences","Pfizer"],"completion_date":{"date":"2030-09-30","type":"ESTIMATED"},"conditions":["Metastatic Breast Cancer"],"enrollment":{"count":1132,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Capecitabine","otherNames":["RO0091978"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["RO5541267"],"type":"DRUG"},{"name":"Ipatasertib","otherNames":[],"type":"DRUG"},{"name":"SGN-LIV1A","otherNames":["RO7235441, Ladiratuzumab vedotin"],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"Chemotherapy (Gemcitabine + Carboplatin or Eribulin)","otherNames":[],"type":"DRUG"},{"name":"Selicrelumab","otherNames":[],"type":"DRUG"},{"name":"Tocilizumab","otherNames":["RO4877533"],"type":"DRUG"},{"name":"Nab-Paclitaxel","otherNames":["RO0247506"],"type":"DRUG"},{"name":"Sacituzumab Govitecan","otherNames":["RO7445735"],"type":"DRUG"},{"name":"Abemaciclib","otherNames":["RO7071651"],"type":"DRUG"},{"name":"Fulvestrant","otherNames":[],"type":"DRUG"},{"name":"Ribociclib (Dose #1)","otherNames":["RO7072612"],"type":"DRUG"},{"name":"Inavolisib (Dose #1)","otherNames":["GDC-0077, RO7113755"],"type":"DRUG"},{"name":"Trastuzumab Deruxtecan","otherNames":[],"type":"DRUG"},{"name":"Ribociclib (Dose #2)","otherNames":["RO7072612"],"type":"DRUG"},{"name":"Letrozole","otherNames":[],"type":"DRUG"},{"name":"Inavolisib (Dose #2)","otherNames":["GDC-0077, RO7113755"],"type":"DRUG"},{"name":"Empagliflozin","otherNames":[],"type":"DRUG"},{"name":"Palbociclib","otherNames":[],"type":"DRUG"},{"name":"Metformin","otherNames":[],"type":"DRUG"},{"name":"Atirmociclib","otherNames":[],"type":"DRUG"},{"name":"Giredestrant","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-09","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2030-09-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Baseline until disease progression or loss of clinical benefit (up to approximately 12 years)"}],"references":[],"start_date":{"date":"2018-03-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03424005"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/morpheus-panbc-nct03424005"}